Company intelligence / Profile preview
Novartis
Basel, Switzerlandnovartis.com ↗
- Ownership
- Public · NVS
- Employees
- ~109000
- Development stage
- Other
01
Overview
Novartis has a diverse portfolio of approved drugs and a competitive pipeline. Recent developments include the $3.1 billion acquisition of Anthos Therapeutics to regain control of abelacimab, a Factor XI inhibitor for stroke prevention. The company has faced challenges with its MorphoSys acquisition, as pelabresib for myelofibrosis has shown mixed results, and has discontinued its BCMA-targeting CAR-T project durcabtagene autoleucel.[6][10]
- Therapeutic areas
- CardiovascularRheumatologyDermatologyHematologyOncologyNeurology
- Modalities
- Small moleculesbiologicsgene therapycell therapy (CAR-T)
- Industry
- Pharma
02
Drug pipeline
759 assets758 more assets in the full pipeline.
03
Partnerships
Previously had partnerships with AstraZeneca (formed Syngenta)GlaxoSmithKline (oncology portfolio acquisition)
04
Financials
- Market cap
- $305.8B
- Total revenue
- $54.8B
- Enterprise value
- $345.2B
Beyond the preview
Go deeper on Novartis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novartis.